TTrialPathMatch Me to Trials
← Back to trials
RecruitingRelapse Multiple MyelomaRefractory Multiple Myeloma

Cilta-Talq Fusion Study: A Phase 1b Study of Talquetamab Bridging Therapy Followed by Ciltacabtagene Autoleucel in Patients With Relapsed/Refractory Multiple Myeloma

Eligible age

18+ yrs

Accepts

All genders

Locations

1 state

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

This is a single-arm, open-label, phase 1b study evaluating the safety and feasibility of using talquetamab as bridging therapy prior to cilta-cel in patients with relapsed and refractory multiple myeloma (RRMM).

Sponsor: Medical College of Wisconsin

You may qualify if…

  • ✓ 1. Age \> 18 years.
  • ✓ 2. Histologically confirmed diagnosis of multiple myeloma with evidence of progressive disease as defined by the IMWG criteria.
  • ✓ 3. Have measurable disease, defined as:
  • ✓ 1. Serum M-protein level ≥ 1.0 g/dL, or
  • ✓ 2. Urine M-protein level ≥ 200 mg/24 hours, or
  • ✓ 3. In patients without a measurable M-protein, an involved light chain level ≥ 10 mg/dL and an abnormal free light chain ratio.
  • ✓ 4. Patient had at least one prior line of therapy (PLOT), including a proteasome inhibitor (PI), an anti-CD38 antibody, and an immunomodulatory drug (IMID).
  • ✓ 5. Patient meets the requirements for the use of talquetamab, as per the most recent FDA prescription information.

You may not qualify if…

  • ✕ 1. Prior treatment:
  • ✕ 1. Adoptive T-cell therapy (e.g., CAR T-cell therapy) at any time prior to enrollment.
  • ✕ 2. Bispecific antibody, investigational or approved, irrespective of its target, at any time prior to enrollment.
  • ✕ 3. Use of talquetamab prior to enrollment.
  • ✕ 4. Any therapy targeting BCMA or GPRC5D, including but not limited to antibody-drug conjugates and/or monoclonal antibodies.
  • ✕ 5. Prior allogeneic stem cell transplant at any time.
  • ✕ 6. Autologous stem cell transplant within 2 months of date of enrollment.
  • ✕ 7. High-dose cytotoxic chemotherapy (e.g., DCEP, KD-PACE, D-PACE) within 28 days of the enrollment date.

Where it's recruiting

Wisconsin

Milwaukee

Source: ClinicalTrials.gov · NCT07093554 · last updated 2026-01-05